UFC bantamweight Rogerio Bontorin has accepted a short suspension after testing positive for a diuretic.
On Wednesday, USADA (the U.S. Anti-Doping Agency), which oversees the UFC’s Anti-Doping Policy, announced that Bontorin had been handed a three-month suspension after hydrochlorothiazide (HCTZ) was found in an out-of-competition urine sample he provided on May 1, 2021.
Per USADA, the culprit appears to have been a contaminated supplement. “Following notification of his positive test, Bontorin provided open containers of two dietary supplements he obtained from a Brazilian compounding pharmacy that he was using prior to his positive test for analysis by a WADA-accredited laboratory,” a press release on the matter stated. “Although no prohibited substances were listed on the supplement product labels, the analysis revealed the presence of HCTZ in the products.”
Because the supplement in question was not USADA certified, Bontorin was still subject to disciplinary action.
Bontorin (17-3, 1NC) would go on to fight two weeks after his positive test was collected, presumably prior to the results being returned. He defeated Matt Schell in a three-round unanimous decision, but missed weight for the bout. The Brazilian hit the scales at 137lbs.
Prior to the victory, Bontorin had lost two straight, to Ray Borg and Kai Kara-France. His suspension is backdated to May 1, 2021 making him already eligible to return to competition.
